alendronate

(redirected from Alendronic acid)
Also found in: Dictionary, Thesaurus, Wikipedia.

alendronate

 [ah-len´dro-nāt]
a calcium-regulating agent used in the form of the sodium salt to inhibit resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy; administered orally.

alendronate

/alen·dro·nate/ (ah-len´dro-nāt) a bisphosphonate calcium-regulating agent used in the form of the sodium salt to inhibit the resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy.

alendronate

(ə-lĕn′drə-nāt′)
n.
A bisphosphonate drug, C4H13NO7P2, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.

alendronate

a bone-resorption inhibitor.
indications This drug is used to treat osteoporosis in postmenopausal women and Paget's disease.
contraindication Known hypersensitivity to biphosphonates prohibits the use of this drug.
adverse effects Side effects include anemia, hypokalemia, hypomagnesemia, hypophosphatemia, osteonecrosis of the jaw, abdominal pain, anorexia, constipation, nausea, vomiting, bone pain, hypertension, urinary tract infection, and fluid overload.

alendronate

A biphosphonate used to treat postmenopausal osteoporosis and Paget’s disease of bone. Alendronate reduces vertebral fractures by 48% and other fractures by 21%, increases bone density by 9% and density of the hip bones by 6% over 3 years of therapy.

Adverse effects
Nausea, stomach pain, constipation, diarrhoea, bloating, headaches, dizziness, swelling of joints (especially of hands and feet).

Mechanism of action
Marked inhibition of bone resorption by inhibiting osteoclastic activity and number of osteoclasts by reducing recruitment, and increasing apoptosis.

alendronate

Fosamax® Endocrinology A biphosphonate used to treat postmenopausal osteoporosis and Paget's disease of bone. See Osteoporosis. Cf Salmon calcitonin.

alendronate

A drug used in the prevention and treatment of post-menopausal OSTEOPOROSIS. A brand name is Fosamax.

Alendronate

A nonhormonal drug used to treat osteoporosis in postmenopausal women.
Mentioned in: Osteoporosis

alendronate

(ă-lendrŏ-nāt)
A bisphosphonate drug used to treat osteoporosis.
[coined term based on parts of the chemical name]
References in periodicals archive ?
8 sgb v with all-time conclusion within the scope of an open-house model within the period from July 18, 2017 to July 31, Active substance combination alendronic acid / colecalciferol (atc-code according to who: m05bb03).
I take alendronic acid supplements once a week and massive calcium tablets the size of dinner plates to help rebuild the bone marrow.
The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Article 130a (8) SGB V on medicinal products with the active substance combination alendronic acid and colecalciferol (ATC: M05BB03) within the framework of an "open-house model".
syringe 0200685 Ikametin 150 mg 0,200,862 Licobondrat 150 mg film-coated tablets 0,166,418 Osagrand 150 mg 0,166,412 Osagrand 3 mg / 3 ml risedronic acid SKL code: 0177298 Melenor 35 mg 0,129,225 Risedronate Teva 35 mg 0,105,178 Risendros 35 mg 0,187,318 Rismyl 35 mg 0,187,849 Tevanel 35 mg zoledronic acid SKL code: 0027103 Aclasta 5 mg alendronic acid and colecalciferol sukl code: 0196943 alendronic acid / Vitamin D3 Teva 70 mg / 0.